Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Study suggesting procaine as exerting neuroprotective properties published
August 26th, 2005
Samaritan Pharmaceuticals Inc. (LIV) announced the journal of Pharmacology published a Samaritan Laboratories study suggesting procaine as exerting neuroprotective properties against Alzheimer disease. Dr. Janet Greeson, CEO of Samaritan stated, "Samaritan's Alzheimer compounds are promising multitargeted drugs. The majority of the scientific community has mainly focused on only one mechanism of action; and despite major breakthroughs in understanding disease progression there hasn't been any major advances in Alzheimer drug development. This study reports disease progression as probably being due to the synergistic action of highly intricate...
Source: Drug Week (2005-08-26)
|
